Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP3 | P08254 | 20/20 | 1.00 |
| ▸ | MMP1 | P03956 | 19/20 | 1.00 |
| ▸ | MMP9 | P14780 | 18/20 | 1.00 |
| ▸ | MMP7 | P09237 | 9/20 | 1.00 |
| ▸ | MMP12 | P39900 | 1/20 | 1.00 |
| ▸ | MMP2 | P08253 | 6/20 | 0.64 |
| ▸ | MMP13 | P45452 | 4/20 | 0.64 |
| ▸ | MMP8 | P22894 | 4/20 | 0.62 |
| ▸ | ADAM17 | P78536 | 7/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10118093 | 0.92 | MMP3 (0.85) | MMP3MMP1MMP9MMP7MMP12 | |
| SCHEMBL7076739 | 0.87 | MMP3 (0.77) | MMP3MMP1MMP9MMP7MMP12 | |
| SCHEMBL7509736 | 0.87 | MMP1 (1.00) | MMP3MMP1MMP9MMP7MMP12 | |
| SCHEMBL7080356 | 0.85 | MMP1 (0.73) | MMP3MMP1MMP9MMP7MMP12 | |
| SCHEMBL7077683 | 0.85 | MMP1 (1.00) | MMP3MMP1MMP9MMP7MMP12 | |
| SCHEMBL7081790 | 0.84 | MMP3 (1.00) | MMP3MMP1MMP9MMP7MMP12 | |
| SCHEMBL11933919 | 0.82 | MMP1 (0.90) | MMP3MMP1MMP9MMP7MMP12 | |
| SCHEMBL7516075 | 0.81 | MMP1 (0.68) | MMP3MMP1MMP9MMP7MMP12 | |
| SCHEMBL7080466 | 0.80 | MMP1 (0.66) | MMP3MMP1MMP9MMP7MMP12 | |
| SCHEMBL7081687 | 0.79 | MMP1 (0.71) | MMP3MMP1MMP9MMP7MMP12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024028417-A1 | NEW COMPOSITION FOR THE TREATMENT AND/OR PREVENTION OF VITILIGO | Institut National de la Santé et de la Recherche Médicale (FR) | 2024-02-08 | — | — | WO | disclosed |
| US-10377818-B2 | Method of treating glioma | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2019-08-13 | — | — | US | disclosed |
| US-9745567-B2 | Compositions and methods for treating multiple sclerosis | REVALESIO CORPORATION (US) | 2017-08-29 | — | — | US | disclosed |
| US-20160222100-A1 | Method of Treating Glioma | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2016-08-04 | — | — | US | disclosed |
| US-20120135959-A1 | Metalloprotein inhibitors containing nitrogen based ligands | REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE | 2012-05-31 | — | — | US | disclosed |
| US-20120135959-A1 | Metalloprotein inhibitors containing nitrogen based ligands | REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE | 2012-05-31 | — | — | US | disclosed |
| US-20100098659-A1 | COMPOSITIONS AND METHODS FOR TREATING MATRIX METALLOPROTEINASE 9 (MMP9)-MEDIATED CONDITIONS | REVALESIO CORPORATION (US) | 2010-04-22 | — | — | US | disclosed |
| US-20100015235-A1 | COMPOSITIONS AND METHODS FOR TREATING MULTIPLE SCLEROSIS | REVALESIO CORPORATION (US) | 2010-01-21 | — | — | US | disclosed |
| US-20100008997-A1 | COMPOSITIONS AND METHODS FOR TREATING ASTHMA AND OTHER LUNG DISORDERS | REVALESIO CORPORATION (US) | 2010-01-14 | — | — | US | disclosed |
| US-20100004189-A1 | COMPOSITIONS AND METHODS FOR TREATING CYSTIC FIBROSIS | REVALESIO CORPORATION (US) | 2010-01-07 | — | — | US | disclosed |
| US-20030130271-A1 | 1,3-Diheterocyclic metalloprotease inhibitors | THE PROCTER & GAMBLE COMPANY | 2003-07-10 | — | — | US | disclosed |
| EP-0927168-B1 | 1,3-DIHETEROCYCLIC METALLOPROTEASE INHIBITORS | PROCTER & GAMBLE (US) | 2002-11-06 | — | — | EP | disclosed |
| US-6469000-B1 | TREATING ARTHRITIS, CANCER, CARDIOVASCULAR DISORDERS, SKIN DISORDERS, OCULAR DISORDERS, INFLAMMATION AND GUM DISEASE | THE PROCTER & GAMBLE CO. | 2002-10-22 | — | — | US | disclosed |
| US-6465474-B1 | TREATMENT OF SUCH AS OSTEOARTHITIS, RHEUMATOID ARTHRITIS, PREVENTION OR ARREST OF TUMOR GROWTH AND METASTASIS, CORNEAL ULCERATION, LACK OF CORNEAL HEALING, MACULAR DEGENERATION, PERIODONTAL DISEASE, GINGIVITIS | THE PROCTER & GAMBLE COMPANY | 2002-10-15 | — | — | US | disclosed |
| US-6150370-A | 1,3-DINITROCYCLIC COMPOUND TREATS NUMEROUS DISEASES CAUSED BY UNDESIRED METALLOPROTEASE ACTIVITY, SUCH AS TUMOR METASTASIS, OSTEOARTHRITIS, RHEUMATOID ARTHRITIS, SKIN INFLAMMATION, ULCERATIONS, AND PERIODONTITIS | THE PROCTER & GAMBLE COMPANY (US) | 2000-11-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100015235-A1 | COMPOSITIONS AND METHODS FOR TREATING MULTIPLE SCLEROSIS | GJA1, GJB2, GPR180 | MMP3 3758/4885MMP1 1996/4885MMP9 2331/4885 |
| US-20120135959-A1 | Metalloprotein inhibitors containing nitrogen based ligands | MMP8, MMP1, TIMP3 | MMP3 11/4885MMP1 2/4885MMP9 4/4885 |
| US-20030130271-A1 | 1,3-Diheterocyclic metalloprotease inhibitors | ADAM17, TIMP3, MMP3 | MMP3 3/4885MMP1 7/4885MMP9 5/4885 |
| US-20100004189-A1 | COMPOSITIONS AND METHODS FOR TREATING CYSTIC FIBROSIS | CFTR, GJB2, KRAS | MMP3 3582/4885MMP1 748/4885MMP9 3488/4885 |
| US-20100098659-A1 | COMPOSITIONS AND METHODS FOR TREATING MATRIX METALLOPROTEINASE 9 (MMP9)-MEDIATED CONDITIONS | MMP9, MMP14, MMP10 | MMP3 6/4885MMP1 12/4885MMP9 1/4885 |
| US-20100008997-A1 | COMPOSITIONS AND METHODS FOR TREATING ASTHMA AND OTHER LUNG DISORDERS | RGS17, RGS16, CHRM3 | MMP3 2197/4885MMP1 1856/4885MMP9 2038/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.